PA
SPRY icon

Profund Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Profund Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Sell
32,199
-20,129
-38% -$173K 0.01% 908
2026
Q1 		$420K Buy
52,328
+9,520
+22% +$91.2K 0.02% 604
2025
Q4 		$499K Buy
42,808
+16,478
+63% +$160K 0.02% 566
2025
Q3 		$265K Buy
26,330
+9,242
+54% +$133K 0.01% 809
2025
Q2 		$298K Buy
17,088
+1,264
+8% +$18.2K 0.01% 695
2025
Q1 		$199K Sell
15,824
-11,046
-41% -$133K 0.01% 908
2024
Q4 		$283K Buy
26,870
+10,467
+64% +$147K 0.01% 796
2024
Q3 		$238K Buy
16,403
+274
+2% +$3.26K 0.01% 955
2024
Q2 		$137K Sell
16,129
-1,303
-7% -$11.6K 0.01% 1025
2024
Q1 		$178K Buy
+17,432
New +$130K 0.01% 1090

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Profund Advisors's SPRY Position: Q2 2026 in Review

Profund Advisors reduced its ARS Pharmaceuticals (SPRY) stake by 38% in Q2 2026, selling an estimated $173K and leaving 32,199 shares worth $258K. The position accounts for 0.01% of the portfolio, ranked #908.

Profund Advisors first reported a position in SPRY in Q1 2024 and has held it in 10 quarters since. The position peaked at $499K in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Profund Advisors held 32,199 shares of ARS Pharmaceuticals worth $258K as of Q2 2026.
  • Profund Advisors sold 20,129 ARS Pharmaceuticals shares in Q2 2026, an estimated $173K.
  • ARS Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #908 holding.
  • Profund Advisors first reported a position in ARS Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Profund Advisors's ARS Pharmaceuticals position peaked at $499K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.